QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.084343v1 315/2/821    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mathews, J. L. Articles by Bidlack, J. M. Search for Related Content PubMed PubMed Citation Articles by Mathews, J. L. Articles by Bidlack, J. M.

BEHAVIORAL PHARMACOLOGY

Characterization of a Novel Bivalent Morphinan Possessing Agonist and µ Agonist/Antagonist Properties

Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, Rochester, New York (J.L.M., J.M.B.); and Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, Belmont, Massachusetts (X.P., W.X., A.Z., S.S.N., J.L.N.)

Previous research has shown that compounds with mixed and µ activity may have utility for the treatment of cocaine abuse and dependence. The present study characterizes the pharmacological profile of a bivalent morphinan that was shown to be a opioid receptor agonist and a µ opioid receptor agonist/antagonist. MCL-145 [bis(N-cyclobutylmethylmorphinan) fumarate] is related to the morphinan cyclorphan and its N-cyclobutylmethyl derivative MCL-101 [3-hydroxy-N-cyclobutylmethyl morphinan S-(+)-mandelate]. MCL-145 consists of two morphinans connected by a spacer at the 3-hydroxy position. This compound had K_i values of 0.078 and 0.20 nM for the and µ opioid receptors, respectively, using radioligand binding assays as shown by Neumeyer et al. in 2003. In the guanosine 5'-O -(3-[³⁵ S]thiotriphosphate) binding assay, MCL-145 produced an E_max value of 80% for the opioid receptor and 42% for the µ opioid receptor. The EC₅₀ values obtained for this compound were 4.3 and 3.1 nM for the and µ opioid receptors, respectively. In vivo MCL-145 produced a full dose-response curve in the 55°C warm water tail-flick test and was equipotent to morphine. The agonist properties of MCL-145 were antagonized by the µ-selective antagonist -funaltrexamine and the -selective antagonist nor-binaltorphimine. MCL-145 also acted as a µ antagonist, as measured by the inhibition of morphine-induced antinociception.

Address correspondence to: Dr. Jean M. Bidlack, Department of Pharmacology and Physiology, Box 711, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave., Rochester, NY 14642-8711. E-mail: jean_bidlack{at}urmc.rochester.edu

This article has been cited by other articles:

				N. Dietis, R. Guerrini, G. Calo, S. Salvadori, D. J. Rowbotham, and D. G. Lambert Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile Br. J. Anaesth., July 1, 2009; 103(1): 38 - 49. [Abstract] [Full Text] [PDF]

				Y.-J. Wang, Y.-M. Tao, F.-Y. Li, Y.-H. Wang, X.-J. Xu, J. Chen, Y.-L. Cao, Z.-Q. Chi, J. L. Neumeyer, A. Zhang, et al. Pharmacological Characterization of ATPM [(-)-3-Aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a Novel Mixed {kappa}-Agonist and {micro}-Agonist/-Antagonist That Attenuates Morphine Antinociceptive Tolerance and Heroin Self-Administration Behavior J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 306 - 313. [Abstract] [Full Text] [PDF]